# Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomized controlled trials

Ya Gao<sup>1,2</sup>, PhD, Professor Gordon Guyatt<sup>2,3</sup>, MD, Timothy M Uyeki<sup>4</sup>, MD, Ming Liu<sup>1,2</sup>, PhD, Yamin Chen<sup>5,6</sup>, MD, Yunli Zhao<sup>7,8</sup>, MD, Yanjiao Shen<sup>9,2</sup>, MD, Jianguo Xu<sup>1</sup>, MD, Qingyong Zheng<sup>1</sup>, MD, Zhifan Li<sup>10</sup>, MD, Wanyu Zhao<sup>11,12</sup>, MD, Shuyue Luo<sup>11,12</sup>, MD, Xiaoyan Chen<sup>13</sup>, MD, Professor Jinhui Tian<sup>1</sup>, PhD, Qiukui Hao<sup>14,2</sup>, MD

1. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

2. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

3. Department of Medicine, McMaster University, Hamilton, ON, Canada

- 4. Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia
- 5. Clinical Nursing Teaching and Research Section, The Second Xiangya Hospital,

Central South University, Changsha, China

6. Xiangya School of Nursing, Central South University, Changsha, China

7. Department of Geriatric Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

8. Chongqing Municipality Clinical Research Center for Geriatrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

9. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University,

Chengdu, Sichuan, China

10. The First Clinical Medical College of Lanzhou University, Lanzhou, China

11. National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China

12. Center of Gerontology and Geriatrics, West China Hospital, Sichuan University,

Chengdu, China

13. Department of Geriatric, Zigong Affiliated Hospital of Southwest Medical University, Zigong, China

14. School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada

**Corresponding author**: Dr Qiukui Hao, School of Rehabilitation Science, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence, and Impact; McMaster University; Hamilton, ON, Canada; Email: haoqiukui@gmail.com. Phone number: +1-365-324-6281.

Word count for text: 3500

Number of references: 52

Number of tables: 3

Number of figures: 2

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

## Summary

**Background:** The optimal antiviral drug for treatment of severe influenza remains unclear. To support updated WHO influenza clinical guidelines, this systematic review and network meta-analysis evaluated antivirals for treatment of patients with severe influenza.

**Methods:** We systematically searched Medline, Embase, CENTRAL, CINAHL, Global Health, Epistemonikos, and ClinicalTrials.gov for randomized controlled trials published through 20 September 2023, that enrolled hospitalized patients with suspected or laboratory-confirmed influenza and compared direct-acting influenza antivirals against placebo, standard care, or another antiviral. We conducted frequentist network meta-analyses to summarize the evidence and evaluated the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. We registered the protocol with PROSPERO, CRD42023456650.

**Findings:** Of 11,878 records, 8 trials with 1,424 participants were included. The effects of oseltamivir, peramivir or zanamivir on mortality compared with placebo or standard care without placebo for seasonal and zoonotic influenza are uncertain. Compared with placebo or standard care, oseltamivir (mean difference (MD) 1.63 days lower, 95% CI 2.81 lower to 0.45 lower) and peramivir (MD 1.73 days lower, 95% CI 3.33 lower to 0.13 lower) may reduce duration of hospitalization for seasonal influenza (low certainty evidence). There were few or no differences between oseltamivir (MD 0.34 days higher, 95% CI 0.86 lower to 1.54 higher; low certainty

evidence), peramivir (MD 0.05 days lower, 95% CI 0.69 lower to 0.59 higher; low certainty evidence) and standard care in time to alleviation of symptoms. There were no differences in adverse events or serious adverse events among oseltamivir, peramivir and zanamivir (very low certainty evidence).

**Interpretation:** In hospitalized patients with severe influenza, oseltamivir and peramivir may reduce duration of hospitalization compared with standard care or placebo. The effects of all antivirals on mortality and other important patient outcomes are very uncertain.

## Funding: WHO.

Keywords: Severe influenza; Antiviral drug; Efficacy; Safety; Network meta-analysis

# **Research in context**

## Evidence before this study

Antivirals are frequently used in the clinical management of people with severe influenza. Previous systematic reviews and meta-analyses have reported that early initiation of neuraminidase inhibitor (NAI) treatment in hospitalized influenza patients may be associated with reduced mortality and length of hospital stay compared with later or no NAI treatment. However, these pairwise meta-analyses mainly focused on the relative effects of one specific class of antivirals (NAIs), did not evaluate the effects of antivirals on severe zoonotic influenza, and did not assess the certainty of evidence. No network meta-analysis has evaluated all available antiviral treatments for severe influenza. The optimal antiviral drug for treatment of patients with severe influenza remains uncertain.

#### Added value of this study

We found low certainty evidence that oseltamivir and peramivir may reduce the duration of hospitalization in patients with severe seasonal influenza compared with placebo or standard care. Great uncertainty remains regarding the effects of oseltamivir, peramivir, and zanamivir on mortality in patients with severe seasonal influenza or zoonotic influenza. There are no important differences in adverse events or serious adverse events associated with oseltamivir, peramivir, or zanamivir for treatment of patients with severe influenza, although the evidence is of very low certainty. The effects of other antivirals, including baloxavir, in patients with severe influenza, on mortality and other important patient outcomes are very uncertain.

## Implications of all the available evidence

Our study provides evidence that oseltamivir and peramivir, relative to placebo or standard care, may reduce the duration of hospitalization for patients with severe seasonal influenza. These findings primarily highlight the uncertainty regarding effects of antivirals for treatment of patients with severe influenza but do provide some justification for their use.

## Introduction

Influenza, a viral respiratory disease, typically causes mild to moderate upper respiratory symptoms that resolve within a week.<sup>1-3</sup> However, a substantial proportion of individuals, particularly those in high-risk groups such as young children, older adults, pregnant women, and persons with chronic medical conditions, can develop severe illness from influenza.<sup>1,4</sup>

Influenza is an important cause of respiratory viral disease among hospitalized patients, with an estimated hundreds of thousands of respiratory deaths worldwide annually with major economic losses.<sup>5-8</sup> Hospitalized patients with seasonal influenza may develop complications, including severe pneumonia, respiratory failure, multi-organ failure, and secondary bacterial infections, that can lead to death.<sup>1,9-12</sup> The case fatality proportion for adults hospitalized with influenza typically ranges from 4% to 8%, but may be higher (>10-15%) during rare pandemics and among immunocompromised individuals.<sup>13</sup> Therefore, identifying effective therapies for severe influenza is of global public health importance.

Antivirals, such as neuraminidase inhibitors (NAIs), are recommended and administered to patients with severe influenza.<sup>14</sup> Systematic reviews and metaanalyses have reported that early NAI treatment may be associated with reduced mortality and shorter length of hospital stay compared with later or no NAI treatment for hospitalized influenza.<sup>15-19</sup> However, these pairwise meta-analyses focused primarily on the relative effects of one class of antivirals (NAIs) for treatment of severe seasonal or pandemic influenza and did not assess effects of

antivirals on zoonotic influenza nor assess the certainty of evidence.<sup>15-19</sup> No network meta-analysis has evaluated all available antiviral treatments for severe influenza. The optimal antiviral drug for treatment of hospitalized patients with influenza remains uncertain.

To support an update of the World Health Organization (WHO) clinical guidelines for influenza,<sup>20</sup> we performed a systematic review and network metaanalysis of randomized controlled trials (RCTs) to assess the efficacy and safety of antivirals for severe influenza.

## Methods

We registered this systematic review protocol with PROSPERO (CRD42023456650) and reported the review according to the guideline of Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) for network meta-analyses.<sup>21</sup>

## Study selection and selection criteria

With the aid of a medical librarian, we searched Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Global Health, Epistemonikos, ClinicalTrials.gov from databases inception through 20 September 2023 (Appendix 1) and reviewed reference lists of relevant systematic reviews to identify additional trials.

Eligible RCTs enrolled hospitalized patients with suspected or laboratoryconfirmed influenza (confirmed by RT-PCR assay, rapid antigen test, or

> immunofluorescence assay) and compared direct-acting antivirals against placebo, standard care without placebo, or another antiviral for treatment of severe influenza. Severe influenza was defined by the WHO as an illness with laboratory-confirmed influenza that requires hospitalization.<sup>20</sup> We focused on antivirals approved for treatment of influenza by the US Food and Drug Administration (FDA) or other regulatory organizations worldwide, including baloxavir, oseltamivir, laninamivir, zanamivir, peramivir, umifenovir, favipiravir, amantadine, and rimantadine.<sup>22</sup> We did not apply restrictions on the type or subtype of influenza virus, publication language, patient age, or dose and administration route of antivirals but excluded studies that investigated influenza prevention with vaccines, Chinese medicines, antivirals combined with adjunctive therapies, or antivirals used for pre- or post-exposure chemoprophylaxis.

> Using Covidence (https://covidence.org/), pairs of reviewers independently screened titles and abstracts of all citations and full texts of potentially eligible records. We checked retractions for all eligible publications; if a study was retracted, we excluded the study from our review.<sup>23</sup> Pairs of reviewers independently extracted data on study characteristics, patient characteristics, characteristics of antivirals, and outcomes (Appendix 2.1). Reviewers resolved discrepancies by discussion or, if necessary, with the assistance of a third party for adjudication.

## Data analysis

The WHO guideline panel identified important patient outcomes as follows: time to alleviation of symptoms, duration of hospitalization, admission to intensive

care unit (ICU), progression to invasive mechanical ventilation, duration of mechanical ventilation, mortality, hospital discharge destination, emergence of antiviral resistance, adverse events, adverse events related to treatments, and serious adverse events. We defined time to alleviation of symptoms as the duration between the start of treatment and the point at which influenza-associated symptoms are alleviated.<sup>24,25</sup>

Using the Hartung-Knapp-Sidik-Jonkman (HKSJ) random-effects model, we conducted pairwise meta-analyses for each direct comparison. For dichotomous outcomes, we calculated risk ratios (RRs) with 95% confidence intervals (CIs) for mortality, progression to invasive mechanical ventilation, emergence of resistance, any adverse events, adverse events related to treatments, and serious adverse events and risk differences (RDs) with 95% CIs for ICU admission. We calculated mean differences (MDs) with 95% CIs for continuous outcomes. When standard deviations (SDs) were missing, we estimated them using the methods described in the Cochrane Handbook.<sup>26</sup> To assess the between-study heterogeneity, we used the I<sup>2</sup> statistic and visually inspected forest plots. For comparisons that included at least 10 studies, to assess publication bias, we planned to use Harbord's test for dichotomous outcomes and Egger's test for continuous outcomes,<sup>27,28</sup> as well as a visual assessment of the funnel plot.

We drew network plots for outcomes using STATA 15.0 (StataCorp, College Station, Texas, USA). We conducted frequentist random-effects network metaanalyses employing a graph-theoretical approach, with the estimator derived from

> weighted least-square regression using the Moore-Penrose pseudoinverse method. <sup>29</sup> Employing the "design-by-treatment" model (global test), we assessed the coherence assumption for the entire network.<sup>30</sup> We calculated indirect estimates from the network by node-splitting and a back-calculation method.<sup>31</sup> To assess local (loop-specific) incoherence within each closed loop of the network, measuring the difference between direct and indirect evidence, we applied the node-splitting method and computed a p-value for the incoherence test.<sup>32</sup> We conducted the analyses in R version 4.2.1 (R Foundation for Statistical Computing).

> To facilitate interpretation of results, we calculated absolute effects using RR estimates and the baseline risk estimates for outcomes in which the summary measure was RR. To estimate absolute effects of antivirals on mortality, the WHO guideline panel recommended use of two baseline risk categories for severe seasonal influenza and zoonotic influenza. We obtained baseline risks of mortality for severe seasonal influenza (30 per 1000) and zoonotic influenza [e.g., avian influenza A(H5N1), A(H5N6), or A(H7N9) virus infections] (387 per 1000) from meta-analyses (results will be reported elsewhere). For other outcomes for which reliable observational data were not available, we used the median baseline risk in the control group of eligible RCTs.

If data were available (at least two trials providing relevant information for each subgroup), we planned to perform the following prespecified within-trial subgroup analyses for patients with severe influenza:

1. Severe influenza etiology: seasonal influenza A and B viruses versus zoonotic

influenza A viruses versus pandemic influenza A viruses (hypothesis: antiviral treatment has lower effectiveness in patients with zoonotic influenza than for seasonal or pandemic influenza).

- Confirmed versus suspected influenza virus infection: (hypothesis: reduced treatment effect in patients with suspected influenza compared to patients with laboratory-confirmed influenza).
- Age: children aged <2 years, children versus adults and adolescents versus elderly (aged ≥65 years) (hypothesis: reduced treatment effect in elderly).

We planned to assess the credibility of significant subgroup effects using the Instrument for assessing the Credibility of Effect Modification Analyses (ICEMAN) tool.<sup>33</sup>

Pairs of reviewers independently evaluated the risk of bias of eligible RCTs using a modified Cochrane risk of bias tool (Appendix 2.2).<sup>34</sup>

We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess certainty of evidence.<sup>35,36</sup> By considering the risk of bias, inconsistency, indirectness, imprecision, publication bias, intransitivity, and incoherence, we rated certainty of evidence for each comparison and outcome as high, moderate, low, or very low.<sup>37,38</sup> To assess intransitivity, we examined the distribution of potential effect modifiers, including age, influenza virus etiology, and confirmed or suspected influenza, across treatment comparisons. We assessed imprecision at the network level using the minimally important difference (MID) for an outcome as a threshold.<sup>39</sup> The WHO guideline panel specified an MID of 0.3% for

> mortality, 1.5% for progression to invasive mechanical ventilation, 1% for admission to ICU, 1% for any adverse events and adverse events related to treatments, 0.5% for serious adverse events, 5% for emergence of antiviral resistance, and 1 day each for duration of hospitalization, time to alleviation of symptoms, and duration of mechanical ventilation. We rated imprecision following GRADE guidance.<sup>40</sup> If incoherence was present, we used the estimate with the higher certainty of direct and indirect evidence as the best estimate. We developed the summary of findings tables in MAGICapp following GRADE guidance.<sup>41,42</sup>

#### Role of the funding source

The funder (World Health Organization) had no role in study design, data collection, analysis, and interpretation, or writing of the manuscript and the decision to submit.

## Results

Our search identified 11878 citations. After screening 8944 titles and abstracts and 459 full texts, 8 RCTs<sup>43-50</sup> proved eligible (Figure 1).

### **Study characteristics**

The 8 eligible trials included a total of 1424 participants (ranging from 30 to 615 per trial). The mean age ranged from 20.5 to 60.3 years, the proportion of men ranged from 42.5% to 78.1%, and the proportion of laboratory-confirmed influenza patients ranged from 78% to 100%. The interventions included oseltamivir, peramivir, zanamivir, rimantadine, zanamivir plus rimantadine, and baloxavir plus NAIs. Direct

comparisons between antivirals and standard care or placebo were available for oseltamivir and peramivir in three trials. The other five trials compared different antivirals: two trials compared oseltamivir against peramivir, one compared oseltamivir against zanamivir, one compared zanamivir and rimantadine against rimantadine alone, while the other trial compared baloxavir plus various NAIs against NAIs alone (Table 1 and Appendix 3).

#### **Risk of bias**

Appendix 4 presents the risk of bias of eligible trials for each outcome. Most biases were due to inadequate allocation concealment and lack of blinding. We rated one trial as low or probably low risk of bias for all reported outcomes.<sup>48</sup>

## **Network meta-analysis**

Six trials were included in the network meta-analysis.<sup>43-45,47,49,50</sup> Figure 2 and Appendix 5 present network plots for each outcome. We did not find substantial between-study heterogeneity (Appendix 6), global incoherence (Appendix 7), or local incoherence (Appendix 8). Table 2, Table 3, and Appendix 9 present GRADE summary of findings. We judged the certainty of evidence to be low or very low for all outcomes. We did not include two eligible trials in the network meta-analysis because both arms of these two trials did not connect with other interventions in the network.<sup>46,48</sup>

## Mortality

The network meta-analysis of mortality included 4 trials of oseltamivir, peramivir or zanamivir involving 813 patients with severe seasonal influenza.<sup>45,47,49,50</sup>

The risk differences for the effect of oseltamivir, peramivir, or zanamivir on mortality when compared with placebo or standard care, or with each other varied from 18 fewer to 4 more per 1000 patients for seasonal influenza and from 232 fewer to 51 more per 1000 patients for zoonotic influenza (very low certainty evidence; Table 2). *Admission to ICU* 

The network meta-analysis of ICU admission included two trials of oseltamivir or peramivir among 235 patients with severe seasonal influenza.<sup>45,47</sup> The risk differences for the effect of oseltamivir or peramivir on ICU admission compared with standard care, or with each other varied from 29 fewer to 43 more per 1000 patients (Appendix 9.1).

## Duration of hospitalization

The network meta-analysis of duration of hospitalization included three trials of oseltamivir or peramivir involving 226 patients with severe seasonal influenza.<sup>44,47,50</sup> The MD in hospitalization duration for oseltamivir compared to placebo or standard care was 1.63 days shorter (95% CI -2.81 to -0.45 days; low certainty evidence). The MD for peramivir compared to placebo or standard care was 1.73 days shorter (95% CI -3.33 to -0.13 days; low certainty evidence). The MD in hospitalization duration for oseltamivir compared with peramivir was 0.10 days longer (95% CI -0.98 to 1.18 days; low certainty evidence; Table 3).

## Time to alleviation of symptoms

The network meta-analysis of time to alleviation of symptoms included three trials with 283 patients with severe seasonal influenza that assessed the effect of oseltamivir or peramivir.<sup>43,45,47</sup> The MD in time to alleviation of symptoms for oseltamivir compared to standard care was 0.34 days longer (95% CI -0.86 to 1.54 days; low certainty evidence). The MD in time to alleviation of symptoms for peramivir compared to standard care was 0.05 days shorter (95% CI -0.69 to 0.59 days; low certainty evidence; Appendix 9.2).

## Adverse events

Two trials with 752 patients with severe influenza provided data on any adverse events and serious adverse events for comparing oseltamivir, peramivir, and zanamivir.<sup>47,49</sup> There were no convincing differences in any adverse events or serious adverse events among oseltamivir, peramivir and zanamivir (very low certainty evidence; Appendix 9.3 and 9.4).

#### Pairwise meta-analysis

Only one study<sup>49</sup> reported data for patients with severe influenza on progression to invasive mechanical ventilation, duration of mechanical ventilation, emergence of resistance, and adverse events related to oseltamivir or zanamivir treatment. We were unable to conduct network meta-analyses for these outcomes but performed pairwise meta-analyses. Compared with zanamivir, the relative risks of oseltamivir on progression to mechanical ventilation, emergence of antiviral resistance, or adverse events related to treatment varied from 1.20 to 2.89 with 95% CIs overlapping with the null effect (very low certainty evidence; Appendix 9.5). The MD in duration of mechanical ventilation was 0.89 days (95% CI -2.32 to 4.10 days, very low certainty evidence; Appendix 9.6).

One study investigated combination treatment with baloxavir plus NAIs versus monotherapy with NAIs.<sup>48</sup> There were few or no differences between baloxavir plus NAIs and NAIs alone on duration of hospitalization (MD 0.31 days shorter, 95% CI - 0.73 to 0.11 days; low certainty evidence) or emergence of antiviral resistance (RD 25 fewer per 1000, 95% CI 39 fewer to 42 more; low certainty evidence). Very low certainty evidence was available on the effects of baloxavir plus NAIs on ICU admission, mechanical ventilation, mortality, or adverse events compared to NAIs alone (Appendix 10).

One study compared combination zanamivir plus rimantadine versus rimantadine alone.<sup>46</sup> Very low certainty evidence was available on the effects of zanamivir plus rimantadine on duration of hospitalization, mortality, or adverse events compared with rimantadine monotherapy (Appendix 11).

#### Additional analysis

Owing to the small number of eligible trials, we could not perform planned subgroup analyses or test for publication bias.

#### Discussion

This network meta-analysis found that oseltamivir and peramivir may reduce duration of hospitalization in patients with severe seasonal influenza compared with placebo or standard care, but the evidence was of low certainty due to limited data from the small number of included RCTs. The effects of oseltamivir, peramivir, or zanamivir on mortality in patients with severe seasonal influenza or severe zoonotic influenza compared with placebo or standard care are very uncertain. Uncertainty

> also remains about the effects of oseltamivir, peramivir, and zanamivir on ICU admission. We did not find evidence of differences in any adverse events or serious adverse events among oseltamivir, peramivir, and zanamivir.

#### Strengths and limitations

This is the first systematic review and network meta-analysis to evaluate the efficacy and safety of different antivirals for treatment of severe influenza. We focused on evidence for approved antivirals from RCTs, assessed the certainty of evidence using the GRADE approach, and presented absolute effects for outcomes. To reflect typical clinical scenarios in practice, we used two separate baseline risks for mortality and separately estimated absolute effects for severe seasonal influenza and zoonotic influenza. The selection of patient-important outcomes, baseline risks, and MID values for outcomes were based on the WHO guideline panel's discussions and suggestions. The WHO panel also reviewed the results and assisted in their interpretation, ensuring a consistent interpretation of the available evidence to date. This systematic review provides the evidence base for the WHO clinical guideline recommendations for antiviral treatment of severe influenza.

Our review has limitations. First, only eight eligible trials were identified, and six trials were included in the network meta-analyses. Only one trial that compared oseltamivir to zanamivir provided data on progression to mechanical ventilation, duration of mechanical ventilation, emergence of resistance, and adverse events related to antiviral treatment.<sup>49</sup> No trials addressed the effects of antivirals versus placebo or standard care on any adverse events or serious adverse events. Therefore,

> uncertainty remains about the effects of antivirals on most outcomes for patients with severe influenza. Second, due to sparse data available, we could not perform any prespecified subgroup analyses. Similarly, the assessments of incoherence and heterogeneity were not applicable for most outcomes and evaluation of publication bias was not applicable for all outcomes. Third, the WHO guideline panel suggested estimating separate absolute effects of antivirals on mortality for hospitalized patients with seasonal influenza and for zoonotic influenza. Since nearly all participants included in the eligible trials were patients with severe seasonal influenza, we estimated the absolute effects for patients with severe zoonotic influenza using the network relative estimates for severe seasonal influenza and baseline risk from a meta-analysis. Fourth, due to rating down the available evidence for risk of bias and imprecision, the certainty of evidence was low or very low for all available comparisons and outcomes. As new data from clinical trials become available, <sup>51,52</sup> we anticipate that the certainty of evidence will improve for the outcomes of interest. To provide up-to-date evidence, we will periodically update this systematic review and network meta-analysis.

### Comparisons with other studies

One previous pairwise meta-analysis of 90 studies (all observational studies) of antiviral treatment of hospitalized patients with pandemic influenza A(H1N1)pdm09 virus infection reported that NAI treatment at any time versus none was associated with a nonsignificant reduction in mortality, but early NAI treatment (≤48 hours after symptom onset) versus late, and early antiviral treatment initiation versus none, was

associated with significant reductions in mortality.<sup>15</sup> Another individual participant data meta-analysis that included 29234 hospitalized patients with pandemic influenza A(H1N1pdm09) virus infection from 78 observational studies, reported that NAI treatment (irrespective of timing) was associated with a reduction in mortality compared with no treatment, and early treatment (within 2 days of symptom onset) was associated with a reduction in mortality relative to later treatment or no treatment.<sup>16</sup> These meta-analyses reported inconsistent results regarding NAI treatment of patients with severe influenza at any time versus no NAI treatment on mortality, mainly because of the different kinds of data (aggregate data versus individual participant data) used.

Our network meta-analysis, including only RCTs, did not substantiate the findings of prior meta-analyses. We assessed the effect of each antiviral on patientimportant outcomes and presented absolute effects for mortality in severe seasonal influenza patients and estimated absolute effects for mortality in severe zoonotic influenza patients, although the very low certainty evidence indicated low confidence in inferences regarding mortality. Moreover, since all included trials did not present data related to the timing of antiviral treatment initiation in relationship to symptom onset, we were unable to examine the effect of the timing of antiviral treatment initiation from symptom onset on outcomes.

One pairwise meta-analysis that included 7 RCTs, addressed different dosages and regimens of NAIs in hospitalized patients with seasonal or pandemic influenza and reported non-significant differences among different antiviral treatment

> regimens on mortality, time to clinical resolution, and viral clearance.<sup>18</sup> These findings regarding time to clinical resolution are consistent with our results of antivirals not having important effects on reducing time to alleviation of symptoms in patients with severe influenza.

> One previous individual participant data meta-analysis that included observational studies of patients hospitalized with pandemic influenza A(H1N1)pdm09 virus infection, reported that NAI treatment started on the day of admission, regardless of time since symptom onset, was associated with a reduction in the length of hospital stay compared with no or later initiation of NAI treatment.<sup>19</sup> Our meta-analysis also found that oseltamivir and peramivir may reduce the duration of hospitalization in patients with severe influenza compared with placebo or standard care. The WHO guideline panel discussed the evidence from observational studies and deemed that they did not provide a higher certainty of evidence for this population compared to the current systematic review of RCTs.

## Implications for future research and practice

Due to limited data from the small number of RCTs of antivirals for treatment of patients with severe seasonal influenza and lack of RCTs for treatment of severe zoonotic influenza, the current level of evidence for antiviral treatment of severe seasonal or zoonotic influenza is of low certainty. Additional clinical trials of antivirals are needed to inform the clinical benefit, safety, and effects on antiviral resistance in patients with severe influenza. Important gaps include better evidence of the effects of antiviral treatment of patients with severe influenza on admission to

ICU, progression to invasive mechanical ventilation, duration of mechanical ventilation, mortality, and emergence of antiviral resistance, and to evaluate the effects of antivirals on outcomes in important subgroup populations, including patients with severe zoonotic influenza.

## Conclusions

Data from RCTs of antiviral treatment of patients with severe influenza are limited. In patients with severe influenza, oseltamivir or peramivir may reduce the duration of hospitalization compared with placebo or standard care. There is high uncertainty of the effects of oseltamivir, peramivir, and zanamivir in patients with severe seasonal or zoonotic influenza on ICU admission and mortality. Sufficiently powered clinical trials in patients with severe influenza due to seasonal influenza virus infections and novel influenza A virus infections are needed to provide higher certainty evidence of the effects of antiviral treatment on important clinical outcomes.

## Contributors

GG, QH, and YG conceived and designed the study. YG and QH designed and performed the search strategy. YG, ML, YZ, SL, and XC screened and selected the articles. YG, ML, YC, YS, JX, QZ, ZL, and WZ extracted the data and assessed the risk of bias. YG and QH analyzed the data. GG and JT supervised the data analyses. YG and QH rated the certainty of evidence. GG provided methodological advice on baseline risk selection and GRADE assessment. YG, GG, TU, and QH interpreted the data. YG and QH drafted the manuscript. YG, GG, TU, and QH revised the manuscript. All authors approved the final version of the manuscript. YG and QH accessed and verified the underlying data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

#### Data sharing statement

Data in this systematic review with meta-analysis are extracted from published studies available on the internet. All processed data are presented in this article and the appendix.

## **Declaration of interests**

We declare no competing interests.

## Acknowledgements

We thank members of the WHO for critical feedback on the review question,

> subgroup and outcome selection, and GRADE judgments: Janet Diaz (World Health Organization, Geneva, Switzerland; email: diazj@who.int); Steven Mcgloughlin (World Health Organization, Geneva, Switzerland; email: mcgloughlins@who.int); Jamie Rylance (World Health Organization, Geneva, Switzerland; email: rylancej@who.int). We thank Rachel Couban (librarian at McMaster University; email: rcouban@mcmaster.ca) for helping with developing the search strategy. We thank Ping Liu (The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; email: ping.liu.cqmu@outlook.com) for contributing to the literature screening.

## References

Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. *Lancet* 2022;
 400(10353): 693-706.

 Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. *Cochrane Database Syst Rev* 2014; **2014**(4): Cd008965.

3. World Health Organization. WHO Influenza (seasonal) fact sheet. Geneva: World Health Organization; 2023. <u>https://www.who.int/news-room/fact-</u> sheets/detail/influenza-(seasonal). Accessed 6 February 2023.

4. Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers 2018;
4(1): 3.

5. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenzaassociated respiratory mortality: a modelling study. *Lancet* 2018; **391**(10127): 1285-300.

6. Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. *J Glob Health* 2019; **9**(2): 020421.

7. Lafond KE, Porter RM, Whaley MJ, et al. Global burden of influenza-associated lower respiratory tract infections and hospitalizations among adults: A systematic review and meta-analysis. *PLoS Med* 2021; **18**(3): e1003550.

8. Lafond KE, Nair H, Rasooly MH, et al. Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982-2012: A Systematic Analysis. *PLoS Med* 

## 2016; 13(3): e1001977.

9. Gill PJ, Ashdown HF, Wang K, et al. Identification of children at risk of influenzarelated complications in primary and ambulatory care: a systematic review and metaanalysis. *Lancet Respir Med* 2015; **3**(2): 139-49.

10. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. *J Infect* 2014; **68**(4): 363-71.

11. Giacchetta I, Primieri C, Cavalieri R, Domnich A, de Waure C. The burden of seasonal influenza in Italy: A systematic review of influenza-related complications, hospitalizations, and mortality. *Influenza Other Respir Viruses* 2022; **16**(2): 351-65.

12. Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. *Influenza Other Respir Viruses* 2016; **10**(5): 394-403.

13. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. *Antivir Ther* 2012; **17**(1 Pt B): 143-57.

14. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. *Clin Infect Dis* 2019; **68**(6): 895-902.

15. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and metaanalysis in hospitalized patients. J Infect Dis 2013; 207(4): 553-63.

16. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. *Lancet Respir Med* 2014; **2**(5): 395-404.

17. Muthuri SG, Venkatesan S, Myles PR, et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data metaanalysis. *Influenza Other Respir Viruses* 2016; **10**(3): 192-204.

18. Tejada S, Campogiani L, Solé-Lleonart C, Rello J. Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials. *Adv Ther* 2020; **37**(6): 2646-66.

19. Venkatesan S, Myles PR, Bolton KJ, et al. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. *J Infect Dis* 2020; **221**(3): 356-66.

20. World Health Organization. Guidelines for the clinical management of severe illness from influenza virus infections. Geneva: World Health Organization; 2021. <a href="https://www.who.int/publications/i/item/9789240040816">https://www.who.int/publications/i/item/9789240040816</a>. Accessed 6 February 2023.

21. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015; **162**(11): 777-84.

22. Kumari R, Sharma SD, Kumar A, et al. Antiviral Approaches against Influenza Virus. *Clin Microbiol Rev* 2023: e0004022.

23. Brown SJ, Bakker CJ, Theis-Mahon NR. Retracted publications in pharmacy systematic reviews. *J Med Libr Assoc* 2022; **110**(1): 47-55.

24. Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. *The Lancet Infectious Diseases* 2020; **20**(10): 1204-14.

25. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. *Lancet* 2015; **385**(9979): 1729-37.

26. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors.
Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated
February 2022). Cochrane Collaboration; 2022.
www.training.cochrane.org/handbook.

27. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in metaanalyses of controlled trials with binary endpoints. *Stat Med* 2006; **25**(20): 3443-57.

28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; **315**(7109): 629-34.

29. Rucker G. Network meta-analysis, electrical networks and graph theory. *Res Synth Methods* 2012; **3**(4): 312-24.

30. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and

inconsistency in network meta-analysis: concepts and models for multi-arm studies.

*Res Synth Methods* 2012; **3**(2): 98-110.

31. Konig J, Krahn U, Binder H. Visualizing the flow of evidence in network metaanalysis and characterizing mixed treatment comparisons. *Stat Med* 2013; **32**(30):

5414-29.

32. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* 2010; **29**(7-8): 932-44.

33. Schandelmaier S, Briel M, Varadhan R, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. *CMAJ* 2020; **192**(32): E901-e6.

34. Guyatt GH, Busse JW. Modification of cochrane tool to assess risk of bias in randomized trials. <u>https://www.evidencepartners.com/resources/methodological-</u>resources/. Accessed January 30, 2023.

35. Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network metaanalysis. *BMJ* 2014; **349**: g5630.

36. Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. *J Clin Epidemiol* 2018; **93**: 36-44.

37. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; **336**(7650): 924-6.

38. Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, et al. GRADE approach to

rate the certainty from a network meta-analysis: addressing incoherence. *J Clin Epidemiol* 2019; **108**: 77-85.

39. Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. *J Clin Epidemiol* 2021; **137**: 163-75.

40. Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. *J Clin Epidemiol* 2022; **150**: 216-24.

41. Carrasco-Labra A, Brignardello-Petersen R, Santesso N, et al. Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format. *J Clin Epidemiol* 2016; **74**: 7-18.

42. Santesso N, Glenton C, Dahm P, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol* 2020; **119**: 126-35.

43. Chen HD, Wang X, Yu SL, Ding YH, Wang ML, Wang JN. Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study. *Open Forum Infectious Diseases* 2021; **8**(1): ofaa562.

44. Dawood FS, Jara J, Gonzalez R, et al. A randomized, double-blind, placebocontrolled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama. *Antiviral research* 2016; **133**(6i7, 8109699): 85-94. 45. de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. *Clinical Infectious Diseases* 2014; **59**(12): e172-85.

46. Ison MG, Gnann JW, Jr., Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. *Antiviral Therapy* 2003; **8**(3): 183-90.

47. Ison MG, Hui DS, Clezy K, et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. *Antiviral Therapy* 2013; **18**(5): 651-61.

48. Kumar D, Ison MG, Mira J-P, et al. Combining baloxavir marboxil with standardof-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. *The Lancet Infectious Diseases* 2022; **22**(5): 718-30.

49. Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. *The Lancet Respiratory Medicine* 2017; **5**(2): 135-46.

50. Ramirez J, Peyrani P, Wiemken T, Chaves SS, Fry AM. A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections. *Clinical Infectious Diseases* 2018; **67**(5): 736-42.

51. Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded

Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study.

Rationale and Design. Ann Am Thorac Soc 2020; 17(7): 879-91.

52. NCT04381936. Randomised Evaluation of COVID-19 Therapy (RECOVERY). 2020.


https://clinicaltrials.gov/study/NCT04381936.

# **Figure legends**


Figure 1. Study selection

# Figure 2. Network plot for mortality

Footnotes: The size of the circle represents the number of participants. The connecting lines represent direct comparisons. The width of the line represents the number of studies.



#### 8 unique randomized controlled trials included



			0							
Study	Trial registration	Country	Number of	Mean	Age	Male %	Comorbidities %	Baseline type of	Confirmed	Treatments
			patients	age	range			influenza %	influenza %	
			randomized	(years)	(years)					
Chen 2021	ChiCTR1900021135	China	40	36.13	18-85	42.50	NR	5.00 (A/H1N1), 95.00	100	Oseltamivir oral 75 mg twice daily for 5
								(A/H3N2)		days
										Peramivir intravenous 300 mg once da 🛱
										for 5 days
Dawood	NCT01690637	El Salvador,	30	NR	0-9	NR	16.67 (asthma)	16.67 (A/H1N1), 70.00	100	Oseltamivir every 12 h for 10 doses. For
2016		Panama						(A/H3N2), 13.33 (B)		children aged 0-11 months, study drug
										was dosed at 3 mg/kg/dose. For children
										aged 12 months, study drug was dosed
										based on standard unit dosing: 30
										mg/dose for children 15 kg, 45 mg for 👼
										children >15e23 kg, 60 mg for
										children >23-40 kg, and 75 mg for
										children >40 kg
										Placebo
de Jong	NCT00958776	21 countries	121	42.58	> 11	52.89	18.18 (COPD or	50.41 (A/H3N2), 20.66	100	Peramivir intravenous 600 mg once da
2014							other chronic lung	(A/2009 H1N1), 3.31		for 5 days
							disease), 4.96	(A/indeterminate),		Standard care
							(history of	23.97 (B), 1.65 (A and		
							congestive heart	В)		
							failure or angina),			걸. Peramivir intravenous 600 mg once daw for 5 days Standard care
							8.26 (diabetes)			-
lson 2003	NR	USA	41	20.48	≥10	78.05	41.46 (pulmonary	92.68 (A), 2.44 (B)	95.12	Zanamivir p <sup>i</sup> us rimantadine. Zanamivir

Table 1. Basic characteristics of eligible RCTs

										me
										medRxiv (which was ng software was ng to inhaled 16 mg four times a day for 5 dayg to to to to to to to to to to to to to
										n prepi was
							disease), 60.98			inhaled 16 mg four times a day for 5 days
							(heart disease),			Rimantadine orally for 5 days. For patien 🛱 🚊
							19.51 (diabetes)			10 to 64 years of age, the dose of
										rimantadine was 100 mg twice daily. For
										persons with severe hepatic dysfunction $\Phi$
										or renal failure (CrCl ≤10 ml/min) and for
										persons 65 years of age or older, the double a
										was reduced to 100 mg once daily $\vec{G} = \frac{\sigma}{2}$
										Rimantadine orally for 5 days. For patien y
										10 to 64 years of age, the dose of
										rimantadine was 100 mg twice daily. Fक्षे 🛱 🙀
										persons with severe hepatic dysfunction
										or renal failure (CrCl ≤10 ml/min) and fਿਲੂਨੋ 🖉
										persons 65 years of age or older, the des
										was reduced to 100 mg once daily
lson 2013	NCT00453999	Australia,	137	59.4	≥18	46.72	19.67	57.74 (A/H3N2), 18.03	100	Peramivir 200 mg intravenously once dai 🛱 S
		Canada,					(COPD/chronic lung	(A/H1N1), 26.23 (B)		for 5 days
		China, New					disease), 7.28			Peramivir 400 mg intravenously once di اللله for 5 days
		Zealand,					(cardiac disease),			for 5 days
		South					13.93 (diabetes)			Oseltamivir oral 75 mg twice daily for 5 kg
		Africa, USA								4.5
Kumar 2022	NCT03684044	25 countries	366	60.29	12-96	52.80	NR	49.38 (A/H1N1), 32.27	100	Baloxavir plus neuraminidase inhibitors. 🚊 🚽
								(A/H3N2), 8.39 (B),		Baloxavir enterally at 40 mg (for 40 kg to <u>මූ ල</u>
								0.93 (multiple		<80 kg bodyweight) or 80 mg (for ≥80 kg b ≤
								influenza subtypes),		bodyweight) on day 1 and day 4, with an a z
								3.73 (unknown)		additional dose on day 7 if no clinical
										n pe
										in this et
										additional dose on day 7 if no clinical in perpetuity.

										Standard care 🛛 👷 🏅
2018										Oseltamivir oral 75 mg twice daily for Area days Standard care
Ramirez	NCT01248715	USA	74	NR	≥ 18	NR	NR	NR	100	Oseltamivir oral 75 mg twice daily for ट्रैड्
							(diabetes), 45.69 (hypertension)	(A/H1N1pdm09 and B), 0.98 (A/H3N2 and B), 0.16 (untyped A and B)		Oseltamivir oral 75 mg twice daily for $\dot{Q}$ doe 5-10 days $\ddot{Q}$ and $\ddot{Q}$ $\ddot{Q}$ and $\ddot{Q}$ $\ddot{Z}$ 
							(coronary artery disease), 8.46 (arrhythmia), 24.88	11.38 (B), 0.16 (A/H1N1pdm09 and A/H3N2), 0.16		Zanamivir intravenous 600 mg twice a day for 5-10 days Oseltamivir oral 75 mg twice daily for
							(asthma), 10.73	(A/H1N1pdm09),		for 5-10 days
larty 2017	NCT01231620	26 countries	615	57	15-101	54.00	21.14 (COPD), 14.63	35.93 (A/H3N2), 29.76	77.96	ة Zanamivir intravenous 300 mg twice a طوم التقليم
										given according to local clinical practice of the second sec
										improvement had occurred on day 5. The standard-of-care neuraminidase inhibito (oseltamivir, zanamivir, or peramivir) wer

NR, not reported.

Comparison	Study results and measurements	Absol	ute effect estimates (p	er 1000)	Absolute difference (95% Cl)	Certainty in effect estimates	Plain language summary
Oseltamivir	Relative risk: 0.53 (95% Cl 0.07 to 4.24)	Seasonal influenza	Standard care/placebo: 30	Oseltamivir: 16	14 fewer per 1000 (95% CI 28 fewer to 97 more)	Very low*	Whether oseltamivir reduces mortality in people with seasonal influenza is very uncertain.
care/placebo	Based on data from 74 participants in 1 study	Zoonotic influenza	Standard care/placebo: 387	Oseltamivir: 205	182 fewer per 1000 (95% CI 360 fewer to 613 more)	Very low*	Whether oseltamivir reduces mortality in people with zoonotic influenza is very uncertain.
Peramivir versus	Relative risk: 0.40 (95% Cl 0.03 to 4.72)	Seasonal influenza	Standard care/placebo: 30	Peramivir: 12	18 fewer per 1000 (95% Cl 29 fewer to 112 more)	Very low*†	Whether peramivir reduces mortality in people with seasonal influenza is very uncertain.
Standard care/placebo participants in 1 study	Zoonotic influenza	Standard care/placebo: 387	Peramivir: 155	232 fewer per 1000 (95% CI 375 fewer to 613 more)	Very low*†	Whether peramivir reduces mortality in people with zoonotic influenza is very uncertain.	
Zanamivir versus Standard	Relative risk: 0.58 (95% Cl 0.06 to 5.29)	Seasonal influenza	Standard care/placebo: 30	Zanamivir: 17	13 fewer per 1000 (95% CI 28 fewer to 129 more)	Very low*†	Whether zanamivir reduces mortality in people with seasonal influenza is very uncertain.
care/placebo	Based on indirect evidence	Zoonotic influenza	Standard care/placebo: 387	Zanamivir: 224	163 fewer per 1000 (95% CI 364 fewer to 613 more)	Very low*†	Whether zanamivir reduces mortality in people with zoonotic influenza is very uncertain.
Oseltamivir versus Peramivir	Relative risk: 1.33 (95% CI 0.11 to 15.87) Based on data from 137	Seasonal influenza	Peramivir: 12	Oseltamivir: 16	4 more per 1000 (95% CI 11 fewer to 178 more)	Very low*	Whether oseltamivir reduces mortality in people with seasonal influenza compared with peramivir is very uncertain.

	participants in 1 study	Zoonotic	Peramivir: 155	Oselta mivir: 206	51 more per 1000		Whether oseltamivir reduces mortality in
		influenza			(95% CI 138 fewer to	Very low*	people with zoonotic influenza compared
					845 more)		with peramivir is very uncertain.
		Seasonal		Oseltamivir: 15	2 fewer per 1000	Very low†‡	Whether oseltamivir reduces mortality in
	Relative risk: 0.91	influenza	Zanamivir: 17		(95% CI 10 fewer to 15		people with seasonal influenza compared
versus Zanamivir Based on data f	(95% CI 0.44 to 1.87)	miluenza			more)		with zanamivir is very uncertain.
	Based on data from 488	Zeenstie	Zanamivir: 224	Oseltamivir: 204	20 fewer per 1000		Whether oseltamivir reduces mortality in
	participants in 1 study	Zoonotic influenza			(95% CI 126 fewer to	Very low*†	people with zoonotic influenza compared
					195 more)		with zanamivir is very uncertain.
		Second			6 fewer per 1000		Whether peramivir reduces mortality in
	Deletive viely 0.08	Seasonal Peramivir: Zanamivir: 17	(95% CI 17 fewer to	Very low*†	people with seasonal influenza compared		
Peramivir versus Zanamivir	Relative risk: 0.68 (95% Cl 0.05 to 9.01)	influenza		11	139 more)		with zanamivir is very uncertain.
	Based on indirect evidence	Zeenetie	Zanamivir: 224	Peramivir:	72 fewer per 1000		Whether peramivir reduces mortality in
	Based on Indirect evidence	Zoonotic influenza		152	(95% CI 213 fewer to	Very low*†	people with zoonotic influenza compared
		mnuenza			776 more)		with zanamivir is very uncertain.

\*Rated down 3 levels for imprecision.

+Rated down 1 level for risk of bias.

**‡**Rated down 2 levels for imprecision.

Comparison	Mean difference (95% CI)	Certainty in effect estimates	Plain language summary		
Oseltamivir versus	-1.63 (-2.81 to	1 + +	Oseltamivir may reduce duration of hospitalization.		
Standard care/placebo	-0.45)	Low†‡			
Peramivir versus	-1.73 (-3.33 to	Low†‡	Peramivir may reduce duration of hospitalization.		
Standard care/placebo	-0.13)	LOW+			
Oseltamivir versus	0.10/0.00 + 1.10	Low†‡	There may be little or no difference between oseltamivir		
Peramivir	0.10 (-0.98 to 1.18)	LOWIŦ	and peramivir in duration of hospitalization.		

# Table 3. GRADE summary of findings for duration of hospitalization for different comparisons

+Rated down 1 level for risk of bias.

**‡**Rated down 1 level for imprecision.